^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    leuprolide acetate for depot suspension

    i
    Other names: TAP-144-SR, TAP-144SR, TAP-144, TAP-144-SR (6M), DWJ 108J, PT105
    Company:
    Generic mfg.
    Drug class:
    GnRH agonist
    Related drugs:
    6d
    A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, Fudan University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)
    |
    HER-2 overexpression • AR positive
    |
    trastuzumab rezetecan (SHR-A1811) • leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide) • tizetatug rezetecan (SHR-A1921)
    6d
    ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov)
    P2, N=393, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 negative
    |
    Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    6d
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    14d
    Case Report: Successful natural conception and delivery in a primary cancer survivor involving the reproductive, respiratory, and endocrine systems auth. (PubMed, Front Oncol)
    She received six cycles of postoperative leuprorelin therapy...The polyp was resected, and the patient received a 14-day course of anti-infective therapy with metronidazole and levofloxacin, after which she was guided by natural conception...It establishes an MDT management pathway encompassing "determination of oncologic remission status, intervention for reversible fertility-compromising factors, and cross-trimester monitoring." This confirms that natural pregnancy is safe and feasible for patients in cancer remission, with multi-disciplinary collaboration and rigorous monitoring. The absence of postpartum neoplasm recurrence and abnormalities in offspring provides a practical paradigm for fertility management in patients with MPNs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    leuprolide acetate for depot suspension
    15d
    OPTIMA-YOUNG: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (clinicaltrials.gov)
    P3, N=3380, Not yet recruiting, UNICANCER
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative • HER-2 expression
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    paclitaxel • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    19d
    Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Not yet recruiting --> Recruiting | Initiation date: Jun 2025 --> Mar 2026
    Enrollment open • Trial initiation date
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Decipher Prostate Cancer Test
    |
    Keytruda (pembrolizumab) • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • leuprolide acetate for depot suspension
    28d
    Retrospective analysis of growth hormone effects on growth and adenoma volume in children with pituitary microadenoma. (PubMed, Transl Pediatr)
    Female and male subgroups differed significantly in PAH and BA-CA improvements (P<0.05). Combined GH and leuprorelin enhances linear growth and delayed bone maturation in children with PM and compromised PAH, without promoting tumor growth or sustained IGF-1 elevation.
    Retrospective data • Journal
    |
    IGF1 (Insulin-like growth factor 1)
    |
    leuprolide acetate for depot suspension
    1m
    Rezvilutamide for High-Risk Prostate Cancer After Surgery (clinicaltrials.gov)
    P=N/A, N=33, Not yet recruiting, Fujian Medical University Union Hospital
    New trial
    |
    leuprolide acetate for depot suspension • AiRuiEn (rezvilutamide)
    1m
    A Clinical Study of KLH-2109 in Patients With Endometriosis (clinicaltrials.gov)
    P3, N=288, Active, not recruiting, Kissei Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    leuprolide acetate for depot suspension • Yselty (linzagolix)
    1m
    Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel. (PubMed, Case Rep Urol)
    A 53-year-old man with metastatic, castration-sensitive prostate cancer (cT3bN1M1b, PSA 9.39 ng/mL, Gleason 4 + 5) underwent androgen deprivation therapy using bicalutamide and leuprorelin. After 73 cycles, chemotherapy was discontinued, and the patient has remained in remission during follow-up. This case highlights the potential efficacy of carboplatin and paclitaxel in treating poorly differentiated CRPC, suggesting the need for further investigation into platinum-based regimens for aggressive prostate cancer variants.
    Journal
    |
    AR (Androgen receptor) • NKX3-1 (NK3 homeobox 1)
    |
    carboplatin • paclitaxel • bicalutamide • leuprolide acetate for depot suspension
    1m
    Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide. (PubMed, Case Rep Oncol Med)
    A 75-year-old man with mHSPC was treated with Apa and leuprorelin. Apa induced CYP3A4 via the PXR pathway, leading to a sustained DDI with CsA. Careful monitoring is necessary when Apa is coadministered with CYP3A4 substrates.
    Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    apalutamide • cyclosporine • leuprolide acetate for depot suspension
    1m
    CLEE011O12001: A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. (2022-503001-38-01)
    P2/3, N=172, Active, not recruiting, Novartis Pharma AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension